Zoetis Inc. $ZTS Shares Bought by Vantage Investment Partners LLC

Vantage Investment Partners LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 28.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 99,292 shares of the company’s stock after acquiring an additional 22,189 shares during the quarter. Vantage Investment Partners LLC’s holdings in Zoetis were worth $12,493,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis in the 4th quarter valued at approximately $25,000. Lodestone Wealth Management LLC bought a new stake in shares of Zoetis in the 4th quarter valued at approximately $30,000. KERR FINANCIAL PLANNING Corp bought a new stake in shares of Zoetis in the 3rd quarter valued at approximately $31,000. Holos Integrated Wealth LLC bought a new stake in shares of Zoetis in the 4th quarter valued at approximately $32,000. Finally, Elyxium Wealth LLC bought a new stake in shares of Zoetis in the 4th quarter valued at approximately $32,000. 92.80% of the stock is currently owned by institutional investors.

Insider Transactions at Zoetis

In other news, Director Paul Bisaro purchased 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael B. Mccallister purchased 3,000 shares of the stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders bought 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of research analyst reports. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. JPMorgan Chase & Co. lowered their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. BTIG Research reiterated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Finally, Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Zoetis currently has a consensus rating of “Hold” and an average target price of $133.92.

Zoetis Stock Up 1.5%

Zoetis stock opened at $81.26 on Friday. The company has a 50-day simple moving average of $108.11 and a 200-day simple moving average of $118.65. The firm has a market capitalization of $34.06 billion, a P/E ratio of 13.48, a P/E/G ratio of 1.31 and a beta of 0.87. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a one year low of $72.38 and a one year high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. Zoetis’s dividend payout ratio is currently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.